CHF-COV Reduced (Chronic Heart Failure With Reduced Ejection Fraction - COngestion eValuation)

Trial statusRecruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age18+
SponsorPr. Nicolas GIRERD

About this trial

Heart failure (HF) is a significant cause of death and the leading cause of hospitalization in patients over 65 years of age. Congestion is the main source of symptoms and the leading cause of hospitalization for HF. Furthermore, congestive signs identified in asymptomatic patients are associated with the risk of developing symptomatic HF. The literature supports a multi-modality / integrative evaluation of congestion, combining clinical examination, laboratory results and ultrasound evaluation.

The main objective of the CHF-COVReduced study is to identify congestion markers (clinical, biological and ultrasound) quantified during a consultation or day hospitalization for the monitoring of chronic HF with reduced left ventricular ejection fraction that are associated with the risk of all-cause death, hospitalization for acute HF or IV diuretics injection in a day hospital.

Eligibility criteria

Qualifiers

Patients with chronic acute heart failure with reduced ventricular ejection fraction admitted in hospital for scheduled day hospitalization or in consultation

Patient with altered (left ventricular ejection fraction <40%) and moderately altered (left ventricular ejection fraction between 40 and 50%) left ventricular ejection fraction

Age ≥18 years

Patients having received complete information regarding the study design and having signed their informed consent form.

Disqualifiers

Comorbidity for which the life expectancy is ≤ 3 months

Dialysis patient (peritoneal dialysis or hemodialysis) or patients with glomerular filtration rate <15 ml/min/m2 at inclusion.

History of lobectomy or pneumonectomy lung surgery

Severe pulmonary or pleural pathology preventing reliable acquisition of lung ultrasound images: severe emphysema, chronic pleurisy, pulmonary fibrosis, etc.

Trial design

Treatments tested in this trial

  • Clinical examination centered on congestion
  • Cardiac, pulmonary, peritoneal, jugular and renal Doppler ultrasounds
  • Blood sample retrieved for biological assessment and biobanking
  • Telephone follow-up
  • Kansas City Cardiomyopathy Questionnaire (KCCQ)

Treatment groups

200 Participants
are divided into 1 treatment group

Sponsors and collaborators

Pr. Nicolas GIRERD

Lead sponsor

Central Hospital, Nancy, France

Sponsor institution